Bills heard in the Senate:
Senate Bill 139: PSILOCYBIN TREATMENT PROGRAM (Charbonneau, E) - This bill establishes a program in Indiana known as the "Psilocybin Treatment Program." Here's an explanation of what this bill aims to do:
Psilocybin Research Fund:
- The bill creates a fund called the "Therapeutic Psilocybin Research Fund." This fund will be administered by the Indiana Department of Health (state department).
Research Assistance:
- The primary purpose of this fund is to provide financial assistance to research institutions within Indiana. These institutions will use the funds to conduct studies and research related to the use of psilocybin, a naturally occurring compound found in certain mushrooms, for the treatment of mental health and other medical conditions.
Clinical Study Requirements:
- The bill sets forth specific requirements and guidelines for conducting clinical studies using psilocybin. These studies are expected to be scientific investigations into the therapeutic potential of psilocybin for addressing various medical conditions, particularly mental health issues.
Reporting Obligations:
- Research institutions conducting these clinical studies are required to prepare and submit detailed reports about their findings and research outcomes. These reports must be submitted to the Interim Study Committee on Public Health, Behavioral Health, and Human Services, the Indiana Department of Health, and the Division of Mental Health and Addiction.
This bill establishes a program that supports research into the therapeutic use of psilocybin, particularly for addressing mental health and other medical conditions. It creates a fund to provide financial assistance to research institutions conducting these studies and outlines specific requirements for conducting such clinical research. The goal is to better understand the potential benefits and risks associated with psilocybin and its use as a treatment option in Indiana.
Yeas: 11; Nays: 0
Senate Bill 3: PRIOR AUTHORIZATION (Johnson, T)
The bill prohibits utilization review entities from requiring prior authorization for medication related to opioid use disorder, which means that individuals seeking medication for opioid use disorder would not need prior authorization to access this treatment. This bill places restrictions on utilization review entities, limiting them to impose prior authorization requirements on less than 1% of specialty or healthcare services and 1% of healthcare providers annually. It also prohibits prior authorization for certain services and drugs, sets requirements for entities that require prior authorization, mandates physician review of adverse determinations and appeals, and provides exemptions if the entity approves 80% of prior authorization requests for a specific healthcare service. Additionally, it repeals outdated prior authorization provisions and makes related adjustments.
Yeas: 10; Nays: 0;
Senate Bill 233: CERTIFIED COMMUNITY BEHAVIORAL HEALTH CLINICS (Crider, M)
This bill mandates that the office of the secretary of family and social services and the division of mental health and addiction must include eligible community mental health centers in either the community mental health services demonstration program, subject to approval, or in a Medicaid state plan amendment or waiver for Medicaid reimbursement for certified community behavioral health clinic services by specific Medicaid providers, in the event Indiana is not approved to participate in the demonstration program.
|